Immune Therapies

Question 1

what is immunoediting

Answer 1

produces low antigenicity tumour cells by selection

Pressure from immune system coupled with genomic instability selects for escape.

Question 2

3 Es of immunoediting

Answer 2

elimination

equilibrium

escape

Question 3

Rituximab

Ofatumomab

Answer 3

B cell lymphoma / NHL

CD20

Question 4

Alemtuzumab

Answer 4

B-CLL/AML/CML

CD52

Question 5

Trastuzumab

Answer 5

Breast, lymphoma

Her-2/neu

Question 6

Cetuximab

Answer 6

colorectal/lung/head and neck

EGFR

Question 7

Bevacizumab

Answer 7

Breast/lung/liver/pancreas/prostate

VEGF

Question 8

Olaratumab

Answer 8

GIST/solid tumours

PDGFR

Question 9

CAR-T cells

Answer 9

• Genetic modification of patient’s T cells (autologous)
• No GvHD, but risk of off-tumour toxicity and CRS Issues
• cost / complexity / kill-switch / single target

Question 10

PTLD

Answer 10

• EBV-driven B cell lymphoma in transplant patients
• Very high mortality rate due to poor treatment options
• SNBTS T cell bank used to treat over 60 patients with survival rate of 59%

Question 11

6 cell therapies for cancer

Answer 11

1. Haematopoietic Stem cells
2. Tumour-Infiltrating T cells (TILs)
3. Dendritic Cell
4. Vaccines
5. NK cells
6. Gamma-delta T cells

Question 12

Answer 12

Question 13

Answer 13

Question 14

Answer 14